bioAffinity Technologies, Inc. BIAF
1.85 USD -0.30 (-13.95%)
Regular-session close
1.89 +0.04 +2.16%
After hours · Nov 19, 4:10 PM ET
1.84 Day range 2.11
1.84 52-week range 80.70
- YTD
- -89.55%
- 1 year
- -91.61%
5D -0.50 (-20.33%)
- Market cap
- 3.37M
- Revenue (ttm)
- 7.32M
- Profit margin
- -119.41%
- EPS (ttm)
- -40.37
- Shares out
- 15.58M
- Forward P/E
- -1.58
- YTD return
- -89.55%
- 1-year return
- -91.61%
- Volume
- 47.06K
- Avg volume
- 3.55M
- Open
- 2.01
- Previous close
- 2.15
- Day's range
- 1.84 – 2.11
- 52-week range
- 1.84 – 80.70
- Beta
- 3.12
- Price target
- 6.00 (+224.3%)
Key statistics
- 50-day average
- 1.28
- 200-day average
- 1.91
- Enterprise value
- 18.47M
- Price / sales
- 2.02
- Price / book
- 1.84
- Revenue growth
- 12047.40%
- Free cash flow
- -4.29M
- Total cash
- 801.31K
- Total debt
- 1.38M
- Return on equity
- -151.52%
- Short % of float
- 2.85%
Fundamental scorecard
7 of 25 checks passed on BIAF’s reported financials
7of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
BIAF Revenue — quarterly 1.07M
BIAF Net income — quarterly -5.28M
BIAF EPS — quarterly -5.89
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.16 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.19 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.21 | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | -0.26 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.26 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -0.20 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 23, 2024 | Maxim Group | init | — | Buy |
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung. It offers CyPath lung, a diagnostic test, for early detection of lung cancer. The company was incorporated in 2014 and is based in San Antonio, Texas.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- bioaffinitytech.com
News
Your note
Sign in to keep a note on BIAF — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDERSON ROBERT A | Director | Stock Award(Grant) | Jun 30, 2024 | 163,936 |
| DIAMOND STUART | Director | Stock Award(Grant) | Jun 30, 2024 | 99,088 |
| EDWARDS JAMES MICHAEL | Chief Financial Officer | Stock Award(Grant) | Nov 4, 2024 | 113,956 |
| GIRGENTI STEVEN | Officer and Director | Stock Award(Grant) | Jun 30, 2024 | 1,074,200 |
| JOYCE ROBY | Director | Stock Award(Grant) | Jun 30, 2024 | 649,745 |
| KNIGHT PETER S | Director | Stock Award(Grant) | Jun 30, 2024 | 117,455 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.67% | 260,869 | 247.82K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.56% | 87,181 | 82.82K | Sep 29, 2024 |
| Captrust Financial Advisors | 0.18% | 27,885 | 26.49K | Sep 29, 2024 |
| Sheaff Brock Investment Advisors, LLC | 0.13% | 20,000 | 19.00K | Sep 29, 2024 |
| State Street Corporation | 0.11% | 17,600 | 16.72K | Sep 29, 2024 |
| Northern Trust Corporation | 0.09% | 13,662 | 12.98K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.41% | 220,227 | 209.22K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.30% | 47,313 | 44.95K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.26% | 40,642 | 38.61K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.09% | 13,704 | 13.02K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.07% | 11,541 | 10.96K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.06% | 9,407 | 8.94K | Oct 30, 2024 |
